Download GenAI Whitepaper

The pharmaceutical industry is undergoing one of the most significant transformations in history with the introduction of Generative AI.

This whitepaper covers how the world’s largest pharmaceutical firms have accelerated drug development throughout the clinical trial process using Generative AI. It evaluates:

The potential of AI to reduce costs and improve efficiency
Key workflows that benefit from automation in clinical trials
Best practices for AI implementation and change management

What does this GenAI whitepaper cover?

Key ways Generative AI is helping pharma firms get drugs to market faster

Automation workflows to accelerate drug development and approval

AI implementation and change management best practices

Each day that a new drug or vaccine gets to market sooner, it creates $1-3 Million in accelerated revenue

It used to take us a minimum of 4 hours to write 1 patient narrative. Now, it takes 4 seconds to write an unlimited number of them.

We wanted to be certain and very accurate around what we produce in these documents that are submitted to health authorities. We want to deliver a draft through Artificial Intelligence that is 100% reliable and needs no further editing by human medical writers. That is what we have achieved with the Yseop collaboration.

Machine learning is a part of every aspect of Lilly’s future, from drug discovery to clinical trials to manufacturing to patient support. Yseop brings a novel approach to regulatory submissions and other reporting, and we see opportunities to bring Yseop’s technology to teams throughout the enterprise.

Access the comprehensive whitepaper

Discover how AI is revolutionizing drug development and approval workflows